Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. Its oncology pipeline consists of NGC-Cap and NGC-Iri (also identified as PCS6422 and PCS11T, respectively) and two non-oncology drugs (PCS12852 and PCS499). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan. PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes. Its pipelines also include VT-7208, a Bruton's tyrosine kinase inhibitor therapy for immune-mediated diseases.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-08-10	$2.610	+1.56%	77,551
26-08-07	$2.570	+11.74%	113,051
26-08-06	$2.300	+5.02%	73,087
26-08-05	$2.190	+3.30%	65,801
26-08-04	$2.120	-0.47%	151,914

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2026-08-10 pm EDT			5-day change	1st Jan Change
2.610 ^USD	+1.56%		+22.54%	-9.38%

Jul. 29	Processa Pharmaceuticals, Inc. acquired Vidya Therapeutics, Inc. for approximately $320 million.	CI
Jul. 29	Processa Pharmaceuticals, Inc. - M&A Call

Market Cap	7.18M 6.21M 5.81M 5.31M 10M 685M 10.16M 68.11M 26.73M 342M 26.95M 26.36M 1.14B	P/E 2024	-0.23x	P/E 2025	-0.28x
Enterprise Value	1.64M 1.42M 1.33M 1.21M 2.29M 157M 2.32M 15.57M 6.11M 78.3M 6.16M 6.03M 261M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	87.69%	Yield 2024 *	-	Yield 2025	-

Jul. 29	Processa Pharmaceuticals, Inc. acquired Vidya Therapeutics, Inc. for approximately $320 million.	CI
Jul. 29	Processa Pharmaceuticals, Inc. - M&A Call
Jul. 29	Processa Pharmaceuticals, Inc. announced that it expects to receive $200 million in funding from a group of investors	CI
Jul. 29	Processa buys Vidya Therapeutics, raises $200 million for drug trials	RE
Jul. 29	Processa Pharmaceuticals, Inc. Announces Appointment of Sheila Gujrathi as Director	CI
Jul. 27	Processa Pharmaceuticals, Inc. announced that it expects to receive $200 million in funding	CI
Jul. 27	Deals of the day-Mergers and acquisitions	RE
May. 07	Processa Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 30	Processa Pharmaceuticals, Inc. Announces Transition of Employment Status of Sian Bigora, Chief Development and Regulatory Officer, Effective May 1, 2026	CI
Mar. 20	Bio-Path Holdings, Inc. Announces Scientific Advisory Board Appointments, Effective February 10, 2026	CI
Mar. 18	Processa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 17	Processa Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
Feb. 19	Processa Pharmaceuticals, Inc. Announces Expiration of Binding Term Sheet with Intact Therapeutics	CI

Nov. 05	Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 Pcs499 Study in Fsgs At Asn Kidney Week 2025	CI
24-04-25	Top Midday Gainers	MT
24-04-25	HC Wainwright Starts Processa Pharmaceuticals With Buy Rating, $8 Price Target	MT
23-04-04	Benchmark Adjusts Price Target on Processa Pharmaceuticals to $4 From $9, Keeps Speculative Buy Rating	MT
23-04-03	Oppenheimer Adjusts Processa Pharmaceuticals Price Target to $3 From $5, Maintains Outperform Rating	MT

Processa Pharmaceuticals, Inc. Stock

Stocks

PCSA

US74275C4033

Biotechnology & Medical Research

Valuation: Processa Pharmaceuticals, Inc.

Chart: Processa Pharmaceuticals, Inc.

Latest news : Processa Pharmaceuticals, Inc.

Last Transcript: Processa Pharmaceuticals, Inc.

Analysts' recommendations: Processa Pharmaceuticals, Inc.

Press Releases: Processa Pharmaceuticals, Inc.

News in other languages: Processa Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Processa Pharmaceuticals, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

Jul. 30	Processa Pharmaceuticals : Initial Statement of Beneficial Ownership (Form 3)	PU
Jul. 29	PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS	AQ
May. 07	Processa Pharmaceuticals : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
Jan. 12	Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference	AQ
Jan. 05	Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study	AQ

23-08-24	Graco: un compounder di qualità sotto gli occhi di tutti
23-08-22	Graco Inc.: Un compounder de calidad bajo el radar
23-08-22	Graco : un compounder de qualité sous les radars

1 day	+1.56%
1 week	+22.54%
Current month	+21.40%
1 month	+20.83%
3 months	-4.40%
6 months	+12.02%
Current year	-9.38%

1 week	2.1	2.79
1 month	1.8	3.11
Current year	1.67	3.8
1 year	1.67	14.24
3 years	1.67	450
5 years	1.67	4,495.35
10 years	1.67	125,195.11

Manager	Title	Age	Since
George Ng CEO	Chief Executive Officer	52	2023-08-07
Patrick Lin IRC	Investor Relations Contact	60	2011-03-28
Wendy Guy ADM	Chief Administrative Officer	61	2017-10-03

Director	Title	Age	Since
David Young CHM	Chairman	73	2011-03-28
Justin Yorke CHM	Chairman	60	2022-08-15
Geraldine Pannu BRD	Director/Board Member	56	2020-02-12

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/26/26	Russell Skibsted	Other	Chief Financial Officer	11,883	0.4293%
7/26/26	George Ng	Other	Chief Executive Officer	9,384	0.3390%
7/26/26	Patrick Lin	Other	Founder	8,450	0.3053%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PROCESSA PHARMACEUTICALS, INC.	+1.56%	+22.54%	-55.00%	-98.59%	7.07M
WUXI APPTEC CO., LTD.	+4.21%	+25.56%	+77.96%	+104.49%	68.12B
ARGENX SE	+0.50%	+6.20%	+34.94%	+67.83%	55.18B
INSMED INCORPORATED	+2.78%	+36.87%	+23.00%	+493.09%	28.63B
WUXI BIOLOGICS (CAYMAN) INC.	0.00%	+18.87%	+57.08%	+5.18%	23.99B
BIONTECH SE	-0.93%	+0.60%	-16.89%	-12.00%	23.53B
GENMAB A/S	-0.35%	+7.91%	+44.14%	-22.61%	18.45B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.89%	+10.84%	+31.14%	+628.97%	16.44B
PHARMAESSENTIA CORPORATION	+7.26%	+14.16%	+221.03%	+393.89%	15.83B
EXELIXIS, INC.	-2.05%	-3.81%	+40.40%	+150.40%	13.4B
Average	+1.15%	+11.44%	+45.78%	+171.06%	26.36B
Weighted average by Cap.	+1.64%	+11.47%	+54.01%	+163.11%

	2024	2025
Net sales	-	-
Net income	-11.85M -10.26M -9.59M -8.76M -16.51M -1.13B -16.77M -112M -44.12M -565M -44.5M -43.53M -1.88B	-13.56M -11.74M -10.98M -10.03M -18.9M -1.29B -19.2M -129M -50.5M -647M -50.93M -49.82M -2.16B
Net Debt	-1.12M -968K -905K -827K -1.56M -107M -1.58M -10.61M -4.16M -53.33M -4.2M -4.11M -178M	-5.54M -4.79M -4.48M -4.09M -7.72M -528M -7.84M -52.54M -20.62M -264M -20.79M -20.34M -880M